Medicaid patients will have new options for and access to GLP-1 medications, per the 12/24/2025 article in Fierce Healthcare titled “CMS launching payment model to boost access to GLP-1s in Medicaid, Part D.”
LiverRight providers diagnose and treat liver disease in all 50 US states + DC, via telemedicine.
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis) are fundamentally metabolic diseases, characterized by excess fat in the liver linked to issues with how the body uses energy, often alongside obesity, type 2 diabetes, insulin resistance, and high cholesterol/blood pressure, formerly known as NAFLD/NASH. MASH is a more severe form of MASLD, involving inflammation and liver cell damage, progressing from simple fat buildup.
🧠 CMS Announces New Payment Model – the BALANCE Model
What it is:
The Centers for Medicare & Medicaid Services (CMS) unveiled a new payment model called the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) model. It’s designed to expand and improve coverage of GLP-1 therapies — medications used for metabolic conditions like diabetes and weight management — under Medicaid and Medicare Part D while helping manage costs for patients and taxpayers.
🎯 Key Features
- Negotiated Pricing & Coverage Terms:
CMS will negotiate with drug manufacturers to secure lower net prices and standardized coverage terms for GLP-1 drugs for participating plans and state Medicaid programs. These negotiations can include discussions about out-of-pocket cost limits and evidence-based lifestyle supports like diet and activity counseling. Fierce Healthcare - Voluntary Participation:
The model is optional for state Medicaid programs, Medicare Part D insurers, and drugmakers — none are required to participate. - Staged Rollout:
- Medicaid: expected to begin as early as May 2026.
- Medicare Part D: planned to start in January 2027.
- A short-term GLP-1 payment model will launch in July 2026 to serve as a “bridge” before the full implementation.
- Application Deadlines:
CMS has issued requests for applications to manufacturers and notices of intent for state Medicaid agencies and Part D plans, with responses due by January 8, 2026.
📊 Evaluation and Goals
CMS plans to monitor the BALANCE model through the Center for Medicare and Medicaid Innovation (CMMI). They will track impacts on costs, patient adherence, and health outcomes to see if the model improves access, lowers costs, and enhances patient health.
🟡 Why It Matters
- Potentially greater access to GLP-1 therapies for millions of Medicaid and Medicare beneficiaries at lower costs.
- Encourages lifestyle support alongside medication, reflecting evidence that combining both may improve long-term health outcomes.
- Part of broader efforts to reform drug pricing and access under federal health programs.